Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378326 · ClinicalTrials.gov registry record · NA
Immunotherapy of the Paraneoplastic Syndromes
A NA study, sponsored by Rockefeller University.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT00378326 is a NA study that has completed, run by Rockefeller University. The registered enrollment target is 26 participants.
The verdict
NCT00378326, a NA study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
We treat a subset of patients with paraneoplastic neurologic disorders, including those with Yo-mediated paraneoplastic cerebellar degeneration (PCD), the Hu syndrome, which is most commonly associated with small cell lung cancer (SCLC) - paraneoplastic subacute sensory neuropathy, encephalomyelitis, limbic encephalopathy, autonomic neuropathy - and the Ri Syndrome (a.k.a. Paraneoplastic Opsoclonus-Myoclonus Ataxia), as well as those patients suspected to have a paraneoplastic neurologic disorder but in whom a characteristic antibody has not yet been identified. Our treatment protocol consists of immune suppression therapy using tacrolimus (FK506), a potent inhibitor of lymphocyte proliferation that is commonly used to prevent organ transplant rejection.
Interventions
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-04 |
| Est. Completion | 2014-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378326
The ClinicalTrials.gov registry entry for NCT00378326 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tacrolimus is the first listed.
NCT00378326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00378326 about?
NCT00378326 is a clinical study titled "Immunotherapy of the Paraneoplastic Syndromes". We treat a subset of patients with paraneoplastic neurologic disorders, including those with Yo-mediated paraneoplastic cerebellar degeneration (PCD), the Hu syndrome, which is most commonly associated with small cell lung cancer (SCLC) - paraneoplastic subacute sensory neuropathy, encephalomyelitis...
What is the current status of trial NCT00378326?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2006-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00378326?
The interventions under investigation include: Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00378326?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.